Browse drugs

…H, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–28. doi: 10…

…ion targeted therapy for PAH. In the SLE-PAH group treated with belimumab, rapid and sustained improvements were observed in multiple par…

…ease with highly variable manifestations. New therapies such as belimumab appear to reduce cumulative organ damage and disease flares, im…

…endent clinical trials: BEAT-lupus and CALIBRATE both comparing belimumab after rituximab vs. rituximab. We further evaluated its potenti…

…arning Objectives Discuss the different mechanisms of action of belimumab and anifrolumab and their roles in modulating immune pathways i…

…fections, most notably sepsis and influenza, when compared with belimumab, and these differences became more evident with longer exposure…

…patientsConclusions In this real-world setting of SLE patients, belimumab treatment was associated with decreases in levels of key mediat…

…-confirmed class III/IV LN were randomised to standard therapy (mycophenolate mofetil and corticosteroids; n=30) or standard therapy plus the belimum…

…lare risk, particularly in those achieving sustained remission. Belimumab use during remission emerged as an additional protective factor…

…matched healthy controls. A subgroup of 5 patients treated with Anifrolumab and 5 with Belimumab were evaluated longitudinally, with sample…

…h high baseline serum IgA2 anti-dsDNA antibodies, compared with rituximab alone. This biomarker-enrichment trial was developed from the i…

…plained approximately 8% of the variance in δCLASI (R2 = 0.08). Anifrolumab was the only therapy independently associated with significant …